| |
|
| July 3, 2002 |
Second Phase 3 Pivotal Study of ENBREL (etanercept) Initiated in Psoriasis |
| June 14, 2002 |
New Data Presented on ENBREL® (etanercept), Only Fully-Human TNF Soluble Receptor, Demonstrates Sustained Efficacy and Tolerability Up to 5 Years |
| June 14, 2002 |
Treatment with ENBREL (etanercept) Shows Improvements in Patient Functionality (HAQ Scores) for Both Newly Diagnosed RA Patients And Those with Established Disease |
| June 10, 2002 |
Immunex Participates in Investor Conference in June |
| May 21, 2002 |
Preliminary Phase 2 Data Suggest ABX-EGF Has Single-Agent Anti-Tumor Activity in Advanced Kidney Cancer |
| May 16, 2002 |
Immunex Shareholders Approve Proposed Merger with Amgen Inc. |
| May 2, 2002 |
Immunex to Sell LEUKINE (sargramostim) to Schering AG Germany |
| April 29, 2002 |
Immunex Announces Settlement of Certain Litigations Relating to Merger with Amgen Inc. |
| April 22, 2002 |
Immunex Announces First Quarter 2002 Results |
| April 15, 2002 |
Immunex Secures Additional Manufacturing Capacity For ENBREL® (etanercept) |
| April 9, 2002 |
Immunex Announces Release Date of First Quarter Earnings |
| March 7, 2002 |
Immunex Corporation (NASQ:IMNX) released the following statement in response to a lawsuit filed today by ZymoGenetics, Inc. |
| February 6, 2002 |
Amgen and Immunex Receive Request for Additional Information from the Federal Trade Commission |
| February 6, 2002 |
Genesis Research and Immunex Corporation Sign New Collaboration Agreement |
| January 23, 2002 |
Immunex Posts Record Sales and Net Income for 2001 |
| January 16, 2002 |
ENBREL® (etanercept) Is First Therapy Approved for Treatment of Psoriatic Arthritis |
| January 2, 2002 |
Immunex Announces Release Date of Fourth Quarter Earnings And Investor Conferences for January |
| |
|
| December 17, 2001 |
Amgen to Acquire Immunex for $16 billion in Stock and Net Cash |
| November 28, 2001 |
Immunex Breaks New Ground in Biotech Manufacturing with Start of BioNext Project in Rhode Island |
| November 11, 2001 |
Phase 3 Psoriatic Arthritis Data for ENBREL (etanercept) Announced at a National Scientific Meeting |
| November 11, 2001 |
New Phase 2 Study Shows Ankylosing Spondylitis Patients Respond to ENBREL (etanercept) |
| November 7, 2001 |
Immunex Moves to Create One of the World's Most Advanced Cell Culture Manufacturing Centers |
| November 6, 2001 |
Immunex Issued Three Patents on Innovative Cell Expression System to Advance Drug Development and Manufacturing |
| November 1, 2001 |
Immunex Schedules Investor Conferences for November |
| October 17, 2001 |
Immunex Reports Third Quarter 2001 Results |
| October 16, 2001 |
New Appointments to Immunex Discovery Research Team |
| October 3, 2001 |
Immunex Announces Date of Third Quarter Earnings Release and Investor Conferences for October |
| September 26, 2001 |
Immunex Corporation Appoints Laura Hamill to Vice President, Marketing for ENBREL® (etanercept) |
| September 17, 2001 |
FDA Assigns "Priority Review" Status to ENBREL (etanercept) sBLA |
| September 10, 2001 |
Immunex Expands Commercial Operation with New Sales Team |
| August 20, 2001 |
Immunex Announces Positive Results With ENBREL® (etanercept) in Psoriasis |
| August 14, 2001 |
Immunex Announces Next Step to Boost ENBREL® (etanercept) Production |
| August 13, 2001 |
Immunex, Wyeth-Ayerst Initiate RADIUS, One of The Largest Longitudinal Studies of Rheumatoid Arthritis Patients |
| July 31, 2001 |
Immunex Schedules Investor Conferences for August |
| July 26, 2001 |
Empowering People with Rheumatoid Arthritis (RA) Through Awareness and Education |
| July 18, 2001 |
Immunex Reports Second Quarter 2001 Financial Results |
| July 16, 2001 |
ENBREL® (etanercept) Becomes First Product to be Reviewed by FDA For Treatment of Psoriatic Arthritis |
| July 13, 2001 |
Immunex Moves Interleukin-1 Receptor Type II into Human Clinical Testing |
| July 13, 2001 |
The Immunex All Stars Celebrate 20 Years of Breakthrough Science |
